Key facts
- ClearNote Health’s last known valuation is $244.0M (Jun 2025).
- It has raised $106.8M across 1 recorded rounds; the latest was Early Stage VC ($21.8M) in May 2025.
- Notable investors include Prosperity Capital Management, Mattias Westman, Pathology Asia Holdings.
- ClearNote Health has filed 1 Form D with the SEC, most recently Jun 2025 ($21.8M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for ClearNote Health
Funding rounds
1 roundsAbout ClearNote Health
Developer of a proprietary epigenomic technology designed to detect high-mortality cancers at an early, more treatable stage through a standard blood draw. The company's technology offers non-invasive, cell-free DNA-based assays that track dynamic biological changes using biomarkers and artificial intelligence, enabling high-risk individuals such as those with newly diagnosed type 2 diabetes or predisposition to pancreatic and ovarian cancers to access early detection and improved treatment outcomes.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2016
- Employees
- 49
- Website
- clearnotehealth.com/
- Ownership
- Privately Held (backing)
ClearNote Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ClearNote Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ClearNote Health in its N-PORT filings yet. We sweep new filings monthly.